291 related articles for article (PubMed ID: 17360984)
1. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes.
Xu G; Kaneto H; Laybutt DR; Duvivier-Kali VF; Trivedi N; Suzuma K; King GL; Weir GC; Bonner-Weir S
Diabetes; 2007 Jun; 56(6):1551-8. PubMed ID: 17360984
[TBL] [Abstract][Full Text] [Related]
2. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
3. Incretin hormone receptors are required for normal beta cell development and function in female mice.
Omar B; Ahlkvist L; Yamada Y; Seino Y; Ahrén B
Peptides; 2016 May; 79():58-65. PubMed ID: 27020250
[TBL] [Abstract][Full Text] [Related]
4. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.
Shu L; Matveyenko AV; Kerr-Conte J; Cho JH; McIntosh CH; Maedler K
Hum Mol Genet; 2009 Jul; 18(13):2388-99. PubMed ID: 19386626
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets.
Zhou J; Livak MF; Bernier M; Muller DC; Carlson OD; Elahi D; Maudsley S; Egan JM
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E538-47. PubMed ID: 17505054
[TBL] [Abstract][Full Text] [Related]
7. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of corn zein hydrolysate stimulates GLP-1 and GIP secretion and improves glucose tolerance in male normal rats and Goto-Kakizaki rats.
Higuchi N; Hira T; Yamada N; Hara H
Endocrinology; 2013 Sep; 154(9):3089-98. PubMed ID: 23798598
[TBL] [Abstract][Full Text] [Related]
9. Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy.
Moffett RC; Vasu S; Thorens B; Drucker DJ; Flatt PR
PLoS One; 2014; 9(6):e96863. PubMed ID: 24927416
[TBL] [Abstract][Full Text] [Related]
10. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
11. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
12. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.
Waser B; Beetschen K; Pellegata NS; Reubi JC
Neuroendocrinology; 2011; 94(4):291-301. PubMed ID: 21893952
[TBL] [Abstract][Full Text] [Related]
13. Glucagon receptors on human islet cells contribute to glucose competence of insulin release.
Huypens P; Ling Z; Pipeleers D; Schuit F
Diabetologia; 2000 Aug; 43(8):1012-9. PubMed ID: 10990079
[TBL] [Abstract][Full Text] [Related]
14. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of human incretin receptor missense variants.
Fortin JP; Schroeder JC; Zhu Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2010 Jan; 332(1):274-80. PubMed ID: 19841474
[TBL] [Abstract][Full Text] [Related]
16. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.
Nakagawa A; Satake H; Nakabayashi H; Nishizawa M; Furuya K; Nakano S; Kigoshi T; Nakayama K; Uchida K
Auton Neurosci; 2004 Jan; 110(1):36-43. PubMed ID: 14766323
[TBL] [Abstract][Full Text] [Related]
17. TCF1 links GIPR signaling to the control of beta cell function and survival.
Campbell JE; Ussher JR; Mulvihill EE; Kolic J; Baggio LL; Cao X; Liu Y; Lamont BJ; Morii T; Streutker CJ; Tamarina N; Philipson LH; Wrana JL; MacDonald PE; Drucker DJ
Nat Med; 2016 Jan; 22(1):84-90. PubMed ID: 26642437
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
19. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
20. Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.
Naylor J; Suckow AT; Seth A; Baker DJ; Sermadiras I; Ravn P; Howes R; Li J; Snaith MR; Coghlan MP; Hornigold DC
Biochem J; 2016 Sep; 473(18):2881-91. PubMed ID: 27422784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
